These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 19295254)

  • 1. Molecular targeted therapies for solid tumors: management of side effects.
    Grünwald V; Soltau J; Ivanyi P; Rentschler J; Reuter C; Drevs J
    Onkologie; 2009 Mar; 32(3):129-38. PubMed ID: 19295254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review: side effects of approved molecular targeted therapies in solid cancers.
    Widakowich C; de Castro G; de Azambuja E; Dinh P; Awada A
    Oncologist; 2007 Dec; 12(12):1443-55. PubMed ID: 18165622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
    Newton HB
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapies: a new generation of cancer treatments.
    Gerber DE
    Am Fam Physician; 2008 Feb; 77(3):311-9. PubMed ID: 18297955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity induced by tyrosine kinase inhibitors.
    Orphanos GS; Ioannidis GN; Ardavanis AG
    Acta Oncol; 2009; 48(7):964-70. PubMed ID: 19734999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies: a nursing perspective.
    Kay P
    Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):1-4. PubMed ID: 16616280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multitargeted inhibitors in lung cancer: new clinical data.
    Bar J; Herbst RS; Onn A
    Clin Lung Cancer; 2008; 9 Suppl 3():S92-9. PubMed ID: 19419930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinases as targets in the treatment of solid tumors.
    Giamas G; Man YL; Hirner H; Bischof J; Kramer K; Khan K; Ahmed SS; Stebbing J; Knippschild U
    Cell Signal; 2010 Jul; 22(7):984-1002. PubMed ID: 20096351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapies in solid tumors: monoclonal antibodies and small molecules.
    Weiner LM; Borghaei H
    Hum Antibodies; 2006; 15(3):103-11. PubMed ID: 17065741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translation of recent advances and discoveries in molecular biology and immunology in the diagnosis and treatment of pancreatic cancer.
    Albo D; Farrow B; Berger DH
    Surg Oncol Clin N Am; 2008 Apr; 17(2):357-76, ix. PubMed ID: 18375357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond chemotherapy--demystifying the new 'targeted' cancer treatments.
    Dear R; Wilcken N; Shannon J
    Aust Fam Physician; 2008; 37(1-2):45-9. PubMed ID: 18239753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics.
    Hammond-Thelin LA
    Dermatol Clin; 2008 Jan; 26(1):121-59, ix. PubMed ID: 18023775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA; Lynch TJ
    Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients.
    Roé E; García Muret MP; Marcuello E; Capdevila J; Pallarés C; Alomar A
    J Am Acad Dermatol; 2006 Sep; 55(3):429-37. PubMed ID: 16908348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New targets for therapy of sarcoma.
    Magenau JM; Schuetze SM
    Curr Opin Oncol; 2008 Jul; 20(4):400-6. PubMed ID: 18525335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What kind of rash is it?: deciphering the dermatologic toxicities of biologic and targeted therapies.
    Esper P; Gale D; Muehlbauer P
    Clin J Oncol Nurs; 2007 Oct; 11(5):659-66. PubMed ID: 17962174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.
    Raymond E; Hobday T; Castellano D; Reidy-Lagunes D; García-Carbonero R; Carrato A
    Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():19-26. PubMed ID: 21308478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of signal transduction protein kinases as targets for cancer therapy.
    Mikalsen T; Gerits N; Moens U
    Biotechnol Annu Rev; 2006; 12():153-223. PubMed ID: 17045195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential for molecularly targeted therapy against epidermal growth factor receptor ligands.
    Miyamoto S; Fukami T; Yagi H; Kuroki M; Yotsumoto F
    Anticancer Res; 2009 Mar; 29(3):823-30. PubMed ID: 19414315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.